Reactogenicity and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 in the UK
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Reactogenicity and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 in the UK: A Substudy of Two Randomised Controlled Trials (COV001 and COV002)
Lancet 2021 Sep 01;[EPub Ahead of Print], A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, S Belij-Rammerstorfer, S Bibi, M Bittaye, F Cappuccini, P Cicconi, EA Clutterbuck, S Davies, W Dejnirattisai, C Dold, KJ Ewer, PM Folegatti, J Fowler, AVS Hill, S Kerridge, AM Minassian, J Mongkolsapaya, YF Mujadidi, E Plested, MN Ramasamy, H Robinson, H Sanders, E Sheehan, H Smith, MD Snape, R Song, D Woods, G Screaton, SC Gilbert, M Voysey, AJ Pollard, T LambeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.